Alinia nitazoxanide: Phase II started

Romark began a double-blind, placebo-controlled, U.S. Phase II trial (RM01-2027) in 440 patients to evaluate 500 mg oral Alinia twice daily for 5 days. Chugai, a subsidiary of Roche (SIX:ROG; OTCQX:R...